NDANASALSPRAY, METERED
Approved
Aug 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ASTEPRO is an azelastine hydrochloride nasal spray, a selective H1-receptor antagonist indicated for allergic rhinitis. It provides localized antihistamine activity in the nasal cavity to reduce symptoms of nasal allergies. The metered-dose formulation enables consistent patient dosing and improved compliance.
LOE Approaching
As LOE approaches, the brand team is transitioning from growth to lifecycle defense strategies; headcount may shift toward retention and generic mitigation specialists.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ASTEPRO offers limited new career opportunities due to its LOE-approaching status and zero linked job postings. Professionals assigned to this product should expect a focus on market defense, generic competition management, and operational efficiency rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on ASTEPRO at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.